Johnson and Johnson: Carvykti Significantly Improved Progression-Free Survival and Deepened Responses Versus Two Standard Therapies for Patients With Functional High-Risk Multiple Myeloma
June 04, 2024
June 04, 2024
CHICAGO, Illinois, June 4 (TNSres) -- Johnson and Johnson issued the following news release on June 3, 2024:
Johnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. The data show CARVYKTI(R) (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival (PFS) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for patients with . . .
Johnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. The data show CARVYKTI(R) (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival (PFS) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for patients with . . .